Vimal Mehta | executive |
Vincent O'Neill | executive |
Richard Steinhart | executive |
Greg Harrison | analyst |
Robyn Karnauskas | analyst |
Graig Suvannavejh | analyst |
Sumant Kulkarni | analyst |
Robert Risinger | executive |
Raghuram Selvaraju | analyst |
Colin Bristow | analyst |
Matthew Wiley | executive |
Samir Devani | analyst |
Good morning, and welcome to the BioXcel Therapeutics Conference Call, which will include an update on the company's late-stage clinical programs and a discussion of financial results for the fourth quarter and full year 2023. [Operator Instructions] Just to remind everyone, certain matters discussed in today's conference call and/or answers that may be given to questions as or forward-looking statements. subject to risks and uncertainties related to future events and/or the future financial or business performance of the company. Actual results could differ materially from those anticipated in those forward-looking statements. Risk factors that may affect future results are detailed in the company's quarterly report on Form 10-Q for the quarter ended September 30, 2023, which can be found at www.bioxceltherapeutics.com or on www.sec.gov and which will be updated in its annual report on Form 10-K for the year ended December 31, 2023.
As a reminder, today's call is being recorded.